Enzymology and Metabolism Journal

The Receptor for Advanced Glycation End products: Mechanisms and Therapeutic Opportunities in Obesity and Diabetes

Download PDF

Published Date: January 18, 2017

The Receptor for Advanced Glycation End products: Mechanisms and Therapeutic Opportunities in Obesity and Diabetes

Carmen Hurtado del Pozo1, Alexander Shekhtman2, Ravichandran Ramasamy1, and Ann Marie Schmidt1*

1Diabetes Research Program, Division of Endocrinology, NYU Langone Medical Center, New York, NY, USA

2Department of Chemistry, University at Albany, 1400 Washington Avenue, Albany, New York, NY, USA

*Corresponding author: Ann Marie Schmidt, Department of Medicine, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA, Tel: 212-263-9444; E-mail: annmarie.schmidt@nyumc.org.

Citation: Hurtado Del Pozo C, Shekhtman A, Ramasamy R, Schmidt AM (2017) The Receptor for Advanced Glycation End Products: Mechanisms and Therapeutic Opportunities in Obesity and Diabetes. Enzym Metab J 2(1): 106.

 

Abstract

 

The Receptor for Advanced Glycation EndProducts (RAGE) plays important roles in the pathogenesis of metabolic disorders, including obesity, types 1 and 2 diabetes and diabetic complications. RAGE is recruited through the increased production and decreased removal of its ligand families in obese and diabetic tissues, which are driven by such metabolic stresses as high fat feeding, hyperglycemia, inflammation and oxidative stress. In this review, we summarized the state of knowledge regarding RAGE ligand binding to the extracellular domains of RAGE; the mechanism of RAGE signal transduction through DIAPH1 and its consequences in obesity and diabetic complications; and the implications for human subjects, from biomarkers to therapeutic interventions. This body of work supports targeting the RAGE/DIAPH1 signaling axis in metabolic disorders.

Keywords: Advanced Glycation EndProducts; Obesity; Diabetes; Immunoglobulin; Hyperglycemia

 

Introduction

 

The Receptor for Advanced Glycation Endproducts (RAGE) transduces the biological effects of a diverse group of binding molecules, or ligands. RAGE was first identified for its ability to bind the advanced glycation end products, or AGEs, which accumulate in diverse settings such as diabetes, inflammation, oxidative stress, aging, and ischemia/reperfusion injury [1,2]. In addition to AGEs, distinct ligand families of RAGE, including the S100/calgranulins, high mobility group box 1 (HMGB1), amyloidβ-peptide (Aβ) [3–6], and other ligands such as mac-1, phosphatidylserine (PS) and lysophosphatidic acid (LPA)[7–9] have been identified. The identification of these non-AGE ligands of RAGE expanded the possible milieus in which the biology of RAGE plays pathobiological roles, such as in sterile inflammation and autoimmunity, neurodegeneration (such as Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS)), cancer and metabolic disorders [10–13]. In homeostasis, in rodents, other species and in human subjects, the expression of RAGE is low in all tissues except for the lung. However, in disease, and particularly in the distinct conditions in which RAGE ligands accumulate, the expression of RAGE is higher compared to age-matched or non-diseased controls. Key questions arise as to how is it possible that such diverse ligands bind RAGE and, further, how do these diverse moieties transverse signals via the receptor? In this review, we will consider the current state of knowledge in these key areas and we will present examples of diseases of metabolic dysfunction in which RAGE appears to play contributory mediating roles. Finally, we will address the status of antagonizing RAGE and prospects for clinical translation.

We begin with a review of the complexity of the RAGE domains with respect to ligand binding and how these diverse ligands mediate signal transduction.

 

RAGE – Structure and Ligand Engagement

 

RAGE is a member of the immunoglobulin superfamily of cell surface molecules. Its extracellular region is composed of three immunoglobulin like domains, one V (variable) type domain, followed by two C (constant) domains. These domains are followed by a single hydrophobic transmembrane domain and lastly by a highly charged, short cytoplasmic domain, which has been shown to be essential for RAGE-mediated signal transduction [14]. Most of the ligands of RAGE bind to the V-type immunoglobulin domain. However, a number of studies have suggested that the first two extracellular domains (V-C1) form an integrated unit to facilitate ligand binding [15].

Xie and colleagues used NMR spectroscopy to identify three distinct surfaces on the V-domain capable of binding the RAGE ligand, AGEs: (1) strand C and loop CC’, (2) strand C’, strand F and loop FG, and (3) strand A’ and loop EF [16]. These authors suggested that although the binding affinities for AGEs were low (µM range) for isolated V-domain, constitutive receptor oligomerization facilitated the recognition of AGE-modified proteins with affinities less than 100 nM.

Park and colleagues prepared a 1.5Å crystal of the V-C1 domains [17]. These authors identified that the V-C1 domains contained two key “patches” that were responsible for ligand engagement. First, a large basic patch is required for the effects of binding one of the S100/calgranulins, S100B, and second, a negatively charged patch binds AGE proteins [17]. Interestingly, these authors reported that distinct molecules, including double stranded DNA and double stranded RNA, bound RAGE in these extracellular domains. In a distinct study, Koch and colleagues prepared a 1.85Å crystal of the V-C1 binding domains; their data illustrated that the V-C1 domains functioned as an integrated structural unit [18]. They found that V-C1 contained a large positively charged electrostatic surface, which was consistent with the acidic or negative charges of many of the ligand families. Self association of V-C1 was also shown by these authors in their models [18].

Xue and colleagues examined a solution structure of a carboxy ethyl lysine (CEL) peptide (a specific type of AGE) complex with the V-domain. The studies revealed that the CEL peptide fit into a positively charged cavity on the V-domain and that peptide backbone atoms made specific contact with this domain [19]. Recently, Xue and colleagues further illustrated that distinct AGEs, such as hydroimidazolones, bound specifically to the V-domain, with nM affinity, via multiple contacts with a positively charged surface of the V-domain [20].

Yatime and Andersen showed that the homodimerization of the RAGE molecule was multimodal, that is, in addition to oligomerization of V-C1, additional sites for oligomerization were also proposed in the transmembrane domains through a conserved GxxG motif [21]. These patterns of oligomerization were linked mechanistically to both ligand binding and to signal transduction.

Taken together, this published work illustrates putative mechanisms by which distinct ligand families might engage the same receptor. Indeed, very early studies by Xie and colleagues highlighted that oligomeric forms of ligands might be preferred ligands for RAGE; these researchers showed, through high resolution NMR, that hexameric forms of RAGE ligand S100A12 were the likely RAGE binding forms of this S100, in a process that was calcium-dependent [22]. The work described above considered the extracellular and transmembrane domains of RAGE. In the section to follow, we present the current state of understanding the RAGE intracellular domain, as it is essential for the effects of RAGE ligands on signal transduction.

Top ↑

RAGE Cytoplasmic Domain and Signal Transduction

 

The cytoplasmic domain of RAGE is short and essential for RAGE ligands to stimulate signal transduction. Indeed, in cultured cells and in vivo, using novel transgenic mice in which the cytoplasmic domain of RAGE was deleted in a cell-specific manner, although RAGE ligands still bound the extracellular domains, they were no longer able to initiate RAGE signaling in a range of cell types, such as macrophages, T-lymphocytes, neurons, endothelial cells and smooth muscle cells [23–27]. Two key points may be made regarding these findings: First, multiple different ligands of RAGE were tested in these models, such as AGEs, members of the S100/calgranulin family, and Aß; in each case, RAGE signaling by these ligands required the cytoplasmic domain. Second, these studies, albeit that they illustrated the essential role of the RAGE cytoplasmic domain in RAGE-mediated functions, did not identify the proximate mechanisms by which this domain of RAGE triggered signal transduction.

To address this critical issue, a yeast two hybrid assay was performed in order to identify molecules that bind the cytoplasmic domain of RAGE as a first step to identifying RAGE-dependent signal transduction effector pathways. The results of this experiment, probing for candidate molecules in a lung library, revealed DIAPH1 (diaphanous-1), a member of the form in family, as a putative effector for RAGE signaling [28]. Multiple confirmatory studies, including immunoprecipitation and immunofluorescence microscopy confirmed that in in vitro and cellular systems, RAGE bound DIAPH1, particularly its FH1 (or formin homology) domain 1. Signaling and functional studies were performed, which showed that small interference RNA (siRNA) knockdown of DIAPH1, which had no suppressive effect on RAGE expression, blocked RAGE ligands S100B or carboxy methyl lysine (CML)-AGE-mediated activation of the Rho GTPases rac1 and cdc42 [28]. In functional studies, siRNA-knockdown of DIAPH1 in transformed cells blocked RAGE ligand-mediated cell migration, but had no effect on the migration-stimulating effects of fetal bovine serum (10%), which, at this concentration, is not known to contain RAGE ligands.

Studies in distinct cell types were performed to test the importance of DIAPH1 in RAGE signal transduction. In smooth muscle cells, RAGE and DIAPH1 are expressed. Previous work addressing roles for RAGE in smooth muscle cell responses to neointimal injury (induced in mice by femoral artery endothelial denudation) revealed that genetic (global deletion of Ager – the gene encoding RAGE) or transgenic-mediated expression of cytoplasmic domain-deleted RAGE in smooth muscle cells resulted in significant protection from endothelial denudation injury, that is, the intima/media ratio was greatly reduced [27]. These concepts were tested in mice globally devoid of Diaph1 or their littermate controls. In those studies, quite analogous to results seen with Ager deletion, deletion of Diaph1 significantly reduced intima/media ratio after arterial injury [29]. Primary murine aortic smooth muscle cells were isolated from wild type mice or mice devoid of Diaph1. These studies revealed that RAGE ligand S100B triggered smooth muscle cell migration through a process that was DIAPH1-dependent. The signal transduction mechanisms were traced to S100B/DIAPH1-dependent membrane translocation of c-Src, which caused activation of Rac1 and redox phosphorylation of AKT/glycogen synthase kinase 3β, all processes that were essential for smooth muscle cell migration. Experiments in other cell types supported that DIAPH1 was required for RAGE ligand signal transduction.

In macrophages, it was previously shown that deletion of Ager resulted in protection from hypoxia-mediated upregulation of Egr1, a critical transcription factor involved in pro-inflammatory and pro-thrombotic tissue responses in hypoxic conditions [30]. A key question that arose from these findings was, what were the RAGE ligands generated in this environment, which were responsible for stimulating RAGE? It was shown that hypoxia resulted in a time dependent increase in release of AGEs into cellular supernatant [30]. It was thus logical to ask, does DIAPH1 play roles in hypoxia- or AGE-mediated upregulation of Egr1 in the hypoxic state? To address this question, Xu and colleagues retrieved macrophages from wild type mice and mice devoid of Diaph1 and showed that DIAPH1 was required for hypoxia-mediated upregulation of Egr1 through a pathway including activation of protein kinase C ßII, ERK1/2 (extracellular regulated kinase) and c-Jun NH(2)-terminal kinase signaling [31]. Other cell types in which RAGE ligands were shown to require DIAPH1 for signal transduction were human thyroid cancer cells (S100A4) and microglia (S100B) [32,33].

These studies underscored the need to identify the specific mechanisms by which the RAGE cytoplasmic domain bound DIAPH1. Work by Shekhtman’s laboratory revealed that amino acids 2-15 of the RAGE cytoplasmic domain were ordered, and contained the amino acid residues required for binding to DIAPH1’s FH1 domain [34]. They showed that the interaction surface of the RAGE cytoplasmic domain with the FH1 domain of DIAPH1 consists of a hydrophobic patch formed by the methylene groups of Arg5 and Gln6, and that this is contiguous with a positively charged surface formed by Arg4 and Arg5 [34]. To provide further proof of this relationship, these investigators mutated Arg5 and Gln6 to alanine residues and tested the double mutant. They reported that the double mutant, in contrast to the wild type, bound the FH1 domain of DIAPH1 only weakly, at best.

An essential test of this concept was whether mutation of Arg5 and Gln6 in vivo, in RAGE and DIAPH1-expressing cells, would suppress the effects of RAGE ligands. These experiments were carried out in primary murine aortic smooth muscle cells and revealed that whereas treatment with RAGE ligand S100B stimulated phosphorylation of Akt and cellular migration and proliferation in the wild type cells, introduction of the double mutant blocked these effects [34]. However, the double mutant exerted no suppressive effect on non-RAGE ligand, PDGF-BB, with respect to promotion of smooth muscle cell proliferation or migration. These key findings indicated that the introduction of the double mutant did not broadly block smooth muscle cell functions.

Recently, Xue and colleagues showed that two soluble RAGE monomers (extracellular domains) orient head-to-head and form an asymmetric dimer with the carboxy termini through a process that then recruits DIAPH1, thereby activating signal transduction triggered by RAGE ligands [35].

In summary, extensive evidence is emerging suggesting that the interaction of the RAGE cytoplasmic domain with DIAPH1 is important and essential for RAGE ligand-mediated signal transduction. Further studies are required to determine if DIAPH1 is essential for RAGE effects in all cell types, or, whether there is a cell-restricted pattern.

In the sections to follow, we present a review of the studies linking RAGE and these ligand families to disease states. Because of the diversity of RAGE actions in disease, we have focused this review on RAGE and metabolic diseases.

 

RAGE and Obesity – The Unexpected yet Fascinating Link

 

A first question in in vivo studies was whether or not RAGE and its ligand families are expressed in the relevant disease tissue. For many years, the study of RAGE and AGEs was largely restricted to potential roles in diabetic complications. In the past few years, however, it has become apparent that RAGE and its ligand families are expressed in human and murine obese adipose tissue. Gaens and colleagues first showed that in human “fatty liver,” increased accumulation of CML-AGE epitopes was evident, in parallel with increased expression of RAGE and a host of inflammatory markers such as PAI-1, IL8 and IL6 [36]. Further, it was shown that in human obese adipose tissue, both CML-AGE adducts and RAGE expression were higher than that observed in lean adipose tissue, with expression evident in adipocytes, adipose tissue macrophages and endothelial cells [37]. Intriguingly, it was observed that CML-AGE levels in plasma were actually lower in obese versus lean subjects and experiments in animal models suggested that the AGE adducts were actually “trapped” in the obese adipose tissue, and presumably, more accessible to cell surface RAGE [37]. Other studies, particularly in the Cohort on Diabetes and Atherosclerosis Maastricht Study and Hoorn Study affirmed these findings and linked CML-AGE levels to central obesity [38].

Non-AGE RAGE ligands have also been linked to human obesity; elevated blood levels of S100B were associated with increased adipose tissue mass [39]. In other studies, higher levels of HMGB1 (blood) were associated with obesity in children (vs. the lean state controls) [40]. In vitro, it was shown that inflammation stimulates the release of HMGB1 from adipocytes, thereby, possibly, potentiating adipose inflammation [41].

Studies in vivo affirmed these findings in mice fed high fat diet (60% kcal/fat). Even before the development of diabetes, metabolic tissues displayed increased concentrations of AGE adducts and HMGB1 [42]. Genetic deletion of Ager prevented the deleterious effects of high fat diet on reduced energy expenditure, weight gain, adipose tissue inflammation, and insulin resistance. In contrast, Ager deficiency had no effect on genetic forms of obesity caused by impaired melanocortin signaling. The effects of RAGE were attributed, at least in part, to myeloid RAGE expression, as hematopoietic deficiency of Ager imparted partial protection against high fat diet-induced inflammation and weight gain in high fat feeding [42]. Finally, in adult RAGE-expressing mice, treatment with soluble RAGE, the extracellular ligand-binding domain of RAGE that binds RAGE ligands and blocks their interaction with and activation of the cell surface RAGE, reduces weight gain in mice fed high fat diet (either at onset of high fat diet, or, three weeks into the course of high fat feeding) [42].

Taken together, these data indicated that RAGE plays unexpected and key roles in obesity. Although studies in Ager null mice demonstrated significant effects on prevention of obesity in high fat feeding, the reconstitution of lethally irradiated wild type mice with Ager null bone marrow was significantly, but overall less protective than the global deletion. Studies are actively in progress to identify the distinct RAGE-expressing cells that play significant roles in the response to high fat diet.

Top ↑

RAGE Spares No Tissue in Diabetes: RAGE and Macro/Microvascular Complications in Diabetes

 

Macrovascular Complications

One of the chief causes of morbidity and mortality in diabetes, either type 1 or type diabetes is acceleration of atherosclerosis, with consequent heart attacks and strokes [43]. Burke and colleagues performed a meticulous analysis of hearts and coronary arteries from human subjects with type 2 diabetes versus control individuals. These authors reported that atherosclerotic lesions from diabetic subjects had larger necrotic cores and greater total and distal plaque load [44]. The type 2 diabetic subjects’ lesions had higher content of T lymphocytes and macrophages, as well as HLA DR expression. Further, macrophage infiltration was not dependent on levels of cholesterol or subject age, suggesting that unique diabetes-specific mechanisms underlie these epidemiologic and pathologic findings. Finally, Burke and colleagues showed that expression of RAGE and one of its inflammatory ligands EN-RAGE (or S100A12) was significantly higher in diabetic vs. non-diabetic subjects and was associated with apoptotic macrophages and smooth muscle cells [44]. Other studies localized HMGB1 [45] and AGEs to human atherosclerotic plaques, particularly in regions of plaque vulnerability [46].

The role of RAGE in diabetic atherosclerosis has been addressed extensively in animal models, using multiple modalities of interruption of the ligand – RAGE axis. First, sRAGE was administered to diabetic (insulin-deficient) Apoe null mice fed normal chow in which accelerated atherosclerotic plaques developed, in parallel with increased concentrations of AGE ligands. Administration of sRAGE to diabetic (and non-diabetic) mice was associated with reduced atherosclerotic lesion area, without any effect on levels of glucose, thereby suggesting unique mechanisms that were operative, at least in part, in the diabetic milieu [47]. The finding of the benefits of sRAGE even in non-diabetic mice is not surprising, as the ligands of RAGE, on account of such factors as inflammation and oxidative stress, also accumulate in vascular lesions. Second, genetic deletion of Ager was tested. Soro-Paavonen and colleagues tested the same atherosclerosis-prone mouse model and showed that deletion of Ager in diabetic mice in that background reduced atherosclerosis, in parallel with reduced leukocyte lesion content, lower oxidative stress and reduced levels of RAGE ligands [48]. In a third strategy, Koulis and colleagues performed lethal irradiation of diabetic (streptozotocin) Apoe null mice or Apoe null mice devoid of Ager, followed by reconstitution with either Ager expressing or Ager null bone marrow. The results demonstrated that both compartments – bone marrow and non-bone marrow – were required for the effects of RAGE in diabetic atherosclerosis [49]. Fourth, Harja and colleagues generated transgenic mice in which the cytoplasmic domain RAGE was deleted, primarily in endothelial cells, but not exclusively (as driven by the pre proendothelin 1 promoter). When these mice were bred into the Apoe null background, even without diabetes, atherosclerosis was suppressed compared to RAGE-expressing controls [25]. Finally, Bu and colleagues performed Affymetrix arrays on aortas retrieved from non-diabetic or diabetic Apoe null vs. Apoe null / Ager null mice and reported that a key RAGE-dependent pathway was found to be the ROCK1 branch of the transforming growth factor-beta pathway, particularly in smooth muscle cells [50].

In addition to coronary atherosclerosis, other studies have examined the potential role of RAGE and its ligands in stroke. In human unilateral cerebral infarction, increased expression of RAGE was noted in the ischemic region; the same pattern of RAGE expression was noted in rats after middle cerebral artery occlusion [51]. In animal models, expression of cytoplasmic domain-deleted RAGE in neurons [52], global deletion of Ager [53], transgenic expression of endogenous secretary (a form of soluble) RAGE [53], blockade of HMGB1 [54], or administration of FPS-ZM1 (RAGE inhibitor) [54] beneficially modulated cerebral damage in rodent models of stroke.

Taken together, these considerations suggest that evidence from human tissues places RAGE and its ligands in coronary atherosclerosis and brain tissue in stroke and that blockade of this axis may be of benefit in limiting disease pathology and functional derangements.

Microvascular Complications

RAGE has been studied in many of the microvascular complications of diabetes. In this review, we will focus on complications in the kidney, heart and eye.

Top ↑

Diabetic Nephropathy

 

Multiple studies place RAGE and its ligands in the diabetic kidney and indicate that such localization is not restricted to the diabetic state [55,56]. D’Agati and colleagues established that the podocyte was a principal cell type expressing RAGE in the human kidney, which was upregulated in the diabetic state [56]. Multiple studies in animal models have addressed the role of RAGE in the diabetic kidney and suggest, collectively, that blockade of this axis may be beneficial in diabetic kidney disease.

First, Yamamoto and colleagues developed a transgenic mouse model of diabetes in which RAGE was overexpressed in vascular cells; this resulted in enlargement of the kidney and glomerular hypertrophy, increased mesangial expansion and glomerulosclerosis, and increased albuminuria compared with controls. This was the first RAGE overexpression study to demonstrate the role of the receptor in advancing diabetic kidney disease [57]. Further, in that study, an AGE inhibitor (OPB-9195) attenuated nephropathy in the RAGE overexpression model. Second, in db/db mice, in which severe obesity and hyperglycemia are evident, administration of sRAGE diminished the pathological and functional indices of nephropathy. Additional studies in mice devoid of Ager (C57BL/6) showed attenuation of nephropathy [58]. Third, Inagi and colleagues developed a triple transgenic mouse model with overexpression of megsin, iNOS and RAGE; the triple transgenic demonstrated the highest degrees of glomerular sclerosis vs. the single or double transgenic mice [59]. Fourth, others confirmed the benefits of Ager deletion in the diabetic kidney and suggested that administration of low molecular weight heparin might be a treatment for diabetes associated nephropathy [60]. Fifth, administration of anti-RAGE neutralizing antibodies showed protection against renal complications of diabetes in insulin resistant diabetic db/db mice and in streptozotocin-induced insulin deficient diabetic mice [61,62].

Finally, work in the OVE26 mouse model of diabetic nephropathy provided further support for the role of RAGE in this disorder [63]. This mouse model develops loss of glomerular function, as well as the typical pathological changes in the diabetic kidney and albuminuria [64]. Reiniger and colleagues bred the OVE26 mouse into the FVB Ager null background; compared to Ager-expressing mice, the diabetic mice devoid of Ager demonstrated significant protection against mesangial expansion and glomerulosclerosis, podocyte effacement, thickening of the glomerular basement membrane, and albuminuria. Importantly, the 29% loss of glomerular filtration rate observed in the Ager-expressing OVE26 mice was prevented in those mice devoid of Ager [63]. Importantly, Reiniger and colleagues showed that the levels of the AGE precursor, methylglyoxal, were significantly lower in OVE26 mouse kidney devoid of Ager; they traced the mechanism to higher levels of glyoxalase 1 (GLO1), which detoxifies the AGE precursors, in the Ager null kidney [63]. These authors showed that increased transcription of the genes for Serpine1, Tgfb1, Tgfbi and Col4a1 observed in the diabetic Ager – expressing OVE26 renal cortex was significantly reduced in the kidney cortex of OVE26 mice devoid of Ager. Further, they reported that ROCK1 activity was significantly lower in Ager null OVE26 mice compared with OVE26Ager-expressing kidney cortex [63].

Taken together, these data implicate RAGE in the pathogenesis of functional and pathological derangements in the diabetic kidney and suggested that blockade of the receptor might be protective in this complication.

 

Diabetic Myocardium

 

Induction of diabetes in the rat resulted in a time-dependent increase in AGE accumulation and RAGE expression in the heart [65] and thus suggested that the RAGE axis might contribute to diabetic cardiac dysfunction. Candido and colleagues linked AGEs to diabetic myocardial dysfunction; using ALT-711, an AGE cross link breaker, they showed that this treatment restored optimal collagen properties in the diabetic heart [66].

In the context of RAGE, first, Bucciarelli and colleagues showed that diabetic mice devoid of Ager were protected from ischemia-reperfusion injury in the isolated perfused heart model [26] and they further illustrated that transgenic expression of cytoplasmic domain-deleted RAGE in endothelial cells or macrophages was also protective in the diabetic heart against ischemia/reperfusion. In the RAGE antagonized hearts, lower levels of AGEs were also identified post-ischemia/reperfusion. A key observation was the reduction in markers of cell death in the hearts of the diabetic Ager null mice after injury [26]. Second, in db/db mice, Nielsen and colleagues used a RAGE antibody and showed that treatment of db/db mice prevented the reduction in systolic function and the development of increased left ventricular chamber stiffness. In parallel, they found that expression of collagen genes was reduced significantly by the RAGE antibody [67]. Third, other studies probed the role of the RAGE ligand S100B in the diabetic myocardium and showed that deletion of S100B protected the diabetic heart from the adverse effects of induced myocardial infarction [68].

In summary, these representative studies linked the RAGE ligand/RAGE axis to the pathogenesis of innate damage to the diabetic myocardium as well as to the superimposed adverse effects of ischemia/reperfusion injury.

Top ↑

Diabetic Retinopathy

 

Diabetes is a leading cause of blindness and current therapeutic efforts in diabetes fail to modify the key underlying mechanisms that lead to retinopathy and loss of eyesight [69]. In experimental diabetic retinopathy, RAGE was found to be highly expressed in glial cells [70].

A number of investigations sought to identify if RAGE plays roles in the pathogenesis of diabetic retinal disorders. First, Barile and colleagues administered sRAGE to type 2 diabetic db/db mice devoid of Apoe; these investigators showed that long-term treatment with sRAGE provided significant protection against the neurovascular perturbations that occur in early diabetes [71]. Second, an inhibitor of RAGE ligand HMGB1 prevented retinal vascular permeability [72] and inflammatory and proangiogenic signals in a diabetic animal model [73]. Third, using mice devoid of Ager, McVicar and colleagues showed that these mice, compared with Ager-expressing controls in diabetes, demonstrated less vascular permeability, leukostasis and activation of microglia. Further, formation of acellular capillaries, but not pericyte loss, was reduced in diabetic Ager null mice [74]. Hence, these data provided support for the premise that RAGE might affect the pathogenesis of diabetic retinopathy, at least in part through neural, vascular and glial-dependent mechanisms. Studies in tissue targeted Ager deleted mice will be the next key steps in identifying the proximate RAGE-dependent mechanisms.

 

Other Microvascular Complications and RAGE

 

In addition to roles for RAGE in complications of the kidney, heart and eye, RAGE has also been implicated in diabetes in the following settings, impaired wound healing, neuropathy, peripheral arterial disease, periodontitis, and erectile dysfunction, as examples [75–79]. It is important to note that the protective effects of sRAGE on acceleration of impaired wound healing in diabetic db/db mice indicated that blocking RAGE did not subvert homeostatic mechanisms underlying dermal healing.

 

Tracking RAGE in Human Subjects

 

As discussed above, extensive evidence from human subject diseased tissue localizes RAGE and its ligands to the affected site. However, in practice, diseased tissue is not always readily accessible, especially in a prospective and repetitive manner. How then, may RAGE activity be traced in human subjects?

In fact, soluble forms of RAGE may be detected in human subject plasma or serum. There are two forms of sRAGE that may be detected; they are distinct by their sequences and by the sources of their production. The first form of sRAGE is produced from the naturally-expressed cell surface RAGE through the actions of matrix metalloproteinases (MMPs) and A-Distintegrin and Metalloprotease (ADAM)-10 [80,81]. The second, endogenous secretory (es) RAGE is formed from the actions of pre-mRNA alternative splicing [82]. In general, the cleaved form of sRAGE represents about 80% of the total sRAGE identified in circulation.

In diabetes, a number of studies have suggested links between the circulating levels of these soluble RAGEs and the diabetic state and/or the presence or absence of complications. A recent review of published studies on sRAGEs in diabetes reveals the following highlights: lower levels of sRAGE were found in type 2 diabetic patients with mild cognitive impairment vs. matched control individuals, in parallel with higher levels of serum AGE-peptide [83]; in youth with type 1 diabetes, levels of sRAGE and esRAGE declined over a five year period, independent of gender, diabetes or puberty stage and a positive association was noted with carotid intima-media thickness [84]; in type 2 diabetic subjects enrolled in the ADVANCE trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation), increased levels of sRAGE were associated with new or worsening renal disease over the following five years and higher levels of AGEs were also associated with adverse renal outcomes [85]; and in type 1 and 2 diabetic subjects, skin autofluorescence was positively associated with levels of sRAGE, but not in control subjects [86].

In addition to cross-sectional or prospective studies on levels of sRAGE and esRAGE in diabetic human subjects, other studies have reported on the fate of sRAGEs after therapeutic interventions. Examples of recent studies in this context include: in subjects with type 2 diabetes, treatment with pioglitazone suppressed RAGE expression in peripheral blood mononuclear cells and increased levels of sRAGE and esRAGE [87]; levels of sRAGE increased in morbidly obese subjects who experienced weight loss after bariatric surgery [88]; and in type 2 diabetic subjects, treatment with atorvastatin resulted in increased levels of sRAGE and esRAGE [89]. Others summarized the results of multiple studies in which cardiovascular drugs and nutraceuticals modulated levels of sRAGE [90].

Much work needs to be done to fully establish the ability of sRAGE and/or esRAGE as bona fide biomarkers of diabetes, diabetes complications and the response to therapeutic interventions. It is very possible; however, that consideration of the degree of renal dysfunction and the relation of sRAGEs levels to RAGE ligand levels will be superior to identify specific markers of the state of the RAGE ligand/RAGE axis in human subjects.

Top ↑

Therapeutic Opportunities –Paths to Targeting RAGE in the Clinic

 

Experiments in animal models have used a variety of general strategies to antagonize RAGE and ligand/RAGE interaction. For example, experiments using soluble RAGE in mice suggested that sequestration of the RAGE ligands blocks their binding to and activation of the cell surface receptor and mimic the effects observed by genetic deletion of Ager in a given complication. Other approaches targeting the extracellular domains, with such strategies as RAGE-directed antibodies [61,62] or small molecule antagonists [6,91] have also been tested in animal models.

Recent work based on the discovery that the RAGE cytoplasmic domain bound the formin, DIAPH1, and that this interaction was essential for RAGE-mediated signaling led to the screening of a > 58,000 small molecule library to seek inhibitors of this interaction. As recently reported, 13 such molecules were identified, which bear nanomolar affinities and that bind directly to the RAGE cytoplasmic domain and not to DIAPH1. These 13 small molecules demonstrate efficacy in blockade of RAGE ligand-stimulated cellular signaling and modulation of gene expression and functional properties in cultured immune and vascular cells. Further, in the isolated perfused diabetic heart, many of the compounds imparted significant benefit on suppression of reduced cardiac function after ischemia/reperfusion [92].

In addition to strategies targeting RAGE itself, as noted above, multiple approaches to target RAGE’s ligands, such as antagonism of AGEs [93,94], HMGB1[54,72] and S100/calgranulins [95,96], have also been reported. Ongoing and future research should uncover the feasibility and optimal means of antagonizing RAGE in the clinic.

 

Summary and Perspectives

 

The Figure summarizes current knowledge of the complexities of RAGE signaling and its impact on metabolic stress in obesity and types 1 and 2 diabetes. Although many years of research were dedicated to understanding how RAGE and its ligands contributed to diabetic complications, the fascinating observations regarding the accumulation of RAGE ligands in obesity underscored that the receptor played roles in the development of insulin resistance and the pathogenesis of type 2 diabetes [37–40,42]. Furthermore, in type 1 diabetes, evidence supports that the RAGE ligands/RAGE axis contribute to pancreatic insulitis and cell damage [97,98]. These findings, as well as the prominent roles for S100/calgranulins and HMGB1 in inflammation, broadened the sphere of RAGE actions. Hence, in both types 1 and 2 diabetes, deleterious RAGE ligands are already accumulating prior to the diagnosis of hyperglycemia, thus, perhaps, triggering the very earliest manifestations of macro- and microvascular perturbation in the course of metabolic dysfunction. In this context, also notable in the biology of RAGE is its apparent ability to contribute to regulation of AGE levels. Although the precise mechanisms by which RAGE downregulates Glo1 have yet to be identified, it is apparent that once RAGE is activated, it contributes to a feed forward cycle of continued production and accumulation of its ligand families.

 

Figure 1: RAGE and its ligands at the center of metabolic stress. In human subjects and animal models, the ligands of RAGE accumulate in settings that lead to and characterize metabolic stress. High fat diets and hyperglycemia result in increased production of AGEs. AGEs directly upregulate RAGE and trigger a cascade of inflammatory and oxidative stress that recruits additional ligands of RAGE, the S100/calgranulins and HMGB1. Through both sustained AGE production and RAGE-dependent downregulation of mechanisms that detoxify AGE precursors, AGE production greatly increases. Intriguingly, in both metabolic organs affected by obesity, such as adipose tissue, skeletal muscle and the liver, and affected by insulitis in the pancreatic beta cell, RAGE-dependent actions contribute to the pathogenesis of type 2 diabetes and type 1 diabetes, respectively.  Efforts to quell ligand production and suppression of detoxification, as well as to directly target RAGE may be efficacious in the battle against the pathogenesis of diabetes and its complications. 

 

One of the most significant challenges in identifying new drug targets is the determination of the overall safety profile in targeting a given pathway. These considerations are valid in the context of RAGE. To date, accruing evidence appears to tip the balance in favor of overall safety and efficacy of blocking the receptor. First, homozygous Ager null mice are viable and display normal reproductive capacity and they do not have a reduced life span. Second, multiple studies in rodents have shown that long term blockade of the receptor (sRAGE or RAGE antibodies or small molecules, as cited above), impart no adverse consequences on the animal’s overall health and longevity. Third, a plethora of studies have tested infection models. In murine models of cecal ligation and puncture and in certain forms of pneumonia, deletion of Ager or RAGE blockade is protective, with overall improved host survival [99–101]. However, other studies suggested that increased bacterial outgrowth and dissemination ensued upon E. coli abdominal sepsis in RAGE-blocked animals [102]. In this context, it will be important to continue to study multiple modalities of blocking RAGE in these critical models of innate responses to stress. It is also necessary to note that the means by which these pathogens were introduced in the rodent may not be fully akin to the means and time course for which they infect human subjects.

Finally, as has been extensively noted and identified in one of the earliest reports on RAGE [14], RAGE is highly expressed in the lung, even in homeostasis and without any evidence of disease. A large body of work has been published suggesting that soluble RAGE may be a biomarker for RAGE activity in lung fluids (bronchoalveolar lavage fluid) and that blockade of RAGE may be beneficial in models of acute lung injury, respiratory distress syndromes and chronic airway diseases [103,104]. It should be noted, however, that Englert and colleagues reported distinct effects of Ager blockade/deletion in murine models of asbestosis (harmful) vs. bleomycin induced injury (protective) [105].

All issues considered, although extensive work has been done in the preclinical models and in the human subject probing the role of the RAGE axis as a biomarker, there will be no substitute for long-term exposure of the human subject to antagonism of the ligand/RAGE axis. We posit that the body of accumulating evidence supports that testing the anti-RAGE strategy in the human subject in carefully controlled and performed studies may well be worth the effort. The answers to these critical questions are eagerly anticipated.

Top ↑

References

 

  1. Lennicke C, Rahn J, Heimer N, Lichtenfels R, Wessjohann LA, Seliger B. Redox proteomics: Methods for the identification and enrichment of redox-modified proteins and their applications. Proteomics. 2016;16(2):197-213. doi: 10.1002/pmic.201500268.
  2. Vetter SW. Glycated Serum Albumin and AGE Receptors. Adv Clin Chem. 2015;72:205-75. doi: 10.1016/bs.acc.2015.07.005.
  3. Oesterle A, Bowman MA. S100A12 and the S100/Calgranulins: Emerging Biomarkers for Atherosclerosis and Possibly Therapeutic Targets. Arterioscler Thromb Vasc Biol. 2015;35(12):2496-507. doi: 10.1161/ATVBAHA.115.302072.
  4. Leclerc E, Vetter SW. The role of S100 proteins and their receptor RAGE in pancreatic cancer. Biochim Biophys Acta. 2015;1852(12):2706-11. doi: 10.1016/j.bbadis.2015.09.022.
  5. Pandolfi F, Altamura S, Frosali S, Conti P. Key Role of DAMP in Inflammation, Cancer, and Tissue Repair. Clin Ther. 2016;38(5):1017-28. doi: 10.1016/j.clinthera.2016.02.028.
  6. Walker D, Lue LF, Paul G, Patel A, Sabbagh MN. Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease. Expert Opin Investig Drugs. 2015;24(3):393-9. doi: 10.1517/13543784.2015.1001490.
  7. Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med. 2003;198(10):1507-15.
  8. He M, Kubo H, Morimoto K, Fujino N, Suzuki T, Takahasi T, et al. Receptor for advanced glycation end products binds to phosphatidylserine and assists in the clearance of apoptotic cells. EMBO Rep. 2011;12(4):358-64. doi: 10.1038/embor.2011.28.
  9. Rai V, Toure F, Chitayat S, Pei R, Song F, Li Q, et al. Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling. J Exp Med. 2012;209(13):2339-50. doi: 10.1084/jem.20120873.
  10. Lopez-Diez R, Shekhtman A, Ramasamy R, Schmidt AM. Cellular mechanisms and consequences of glycation in atherosclerosis and obesity. Biochim Biophys Acta. 2016;1862(12):2244-2252. doi: 10.1016/j.bbadis.2016.05.005.
  11. Malik P, Chaudhry N, Mittal R, Mukherjee TK. Role of receptor for advanced glycation end products in the complication and progression of various types of cancers. Biochim Biophys Acta. 2015;1850(9):1898-904. doi: 10.1016/j.bbagen.2015.05.020.
  12. Ray R, Juranek JK, Rai V. RAGE axis in neuroinflammation, neurodegeneration and its emerging role in the pathogenesis of amyotrophic lateral sclerosis. Neurosci Biobehav Rev. 2016;62:48-55. doi: 10.1016/j.neubiorev.2015.12.006.
  13. Reynaert NL, Gopal P, Rutten EP, Wouters EF, Schalkwijk CG. Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; Overview of clinical evidence and potential contributions to disease. Int J Biochem Cell Biol. 2016;81(Pt B):403-418. doi: 10.1016/j.biocel.2016.06.016.
  14. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267(21):14998-5004.
  15. Dattilo BM, Fritz G, Leclerc E, Kooi CW, Heizmann CW, Chazin WJ. The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry. 2007;46(23):6957-70.
  16. Xie J, Reverdatto S, Frolov A, Hoffmann R, Burz DS, Shekhtman A. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J Biol Chem. 2008;283(40):27255-69. doi: 10.1074/jbc.M801622200
  17. Park H, Adsit FG, Boyington JC. The 1.5 A crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding. J Biol Chem. 2010;285(52):40762-70. doi: 10.1074/jbc.M110.169276.
  18. Koch M, Chitayat S, Dattilo BM, Schiefner A, Diez J, Chazin WJ, et al. Structural basis for ligand recognition and activation of RAGE. Structure. 2010;18(10):1342-52. doi: 10.1016/j.str.2010.05.017.
  19. Xue J, Rai V, Singer D, Chabierski S, Xie J, Reverdatto S, et al. Advanced glycation end product recognition by the receptor for AGEs. Structure. 2011;19(5):722-32. doi: 10.1016/j.str.2011.02.013.
  20. Xue J, Ray R, Singer D, Bohme D, Burz DS, Rai V, et al. The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGEs. Biochemistry. 2014;53(20):3327-35. doi: 10.1021/bi500046t.
  21. Yatime L, Andersen GR. Structural insights into the oligomerization mode of the human receptor for advanced glycation end-products. FEBS J. 2013;280(24):6556-68. doi: 10.1111/febs.12556.
  22. Xie J, Burz DS, He W, Bronstein IB, Lednev I, Shekhtman A. Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J Biol Chem. 2007;282(6):4218-31.
  23. Yan SS, Wu ZY, Zhang HP, Furtado G, Chen X, Yan SF, et al. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med. 2003;9(3):287-93.
  24. Arancio O, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D, et al. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J. 2004;23(20):4096-105.
  25. Harja E, Bu DX, Hudson BI, Chang JS, Shen X, Hallam K, et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest. 2008;118(1):183-94.
  26. Bucciarelli LG, Ananthakrishnan R, Hwang YC, Kaneko M, Song F, Sell DR, et al. RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes. 2008;57(7):1941-51. doi: 10.2337/db07-0326.
  27. Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest. 2003;111(7):959-72.
  28. Hudson BI, Kalea AZ, Del Mar Arriero M, Harja E, Boulanger E, D'Agati V, et al. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem. 2008;283(49):34457-68. doi: 10.1074/jbc.M801465200.
  29. Toure F, Fritz G, Li Q, Rai V, Daffu G, Zou YS, et al. Formin mDia1 mediates vascular remodeling via integration of oxidative and signal transduction pathways. Circ Res. 2012;110(10):1279-93. doi: 10.1161/CIRCRESAHA.111.262519.
  30. Chang JS, Wendt T, Qu W, Kong L, Zou YS, Schmidt AM, et al. Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ Res. 2008;102(8):905-13. doi: 10.1161/CIRCRESAHA.107.165308.
  31. Xu Y, Toure F, Qu W, Lin L, Song F, Shen X, et al. Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. J Biol Chem. 2010;285(30):23233-40. doi: 10.1074/jbc.M110.117457.
  32. Bianchi R, Kastrisianaki E, Giambanco I, Donato R. S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release. J Biol Chem. 2011;286(9):7214-26. doi: 10.1074/jbc.M110.169342.
  33. Medapati MR, Dahlmann M, Ghavami S, Pathak KA, Lucman L, Klonisch T, et al. RAGE Mediates the Pro-Migratory Response of Extracellular S100A4 in Human Thyroid Cancer Cells. Thyroid. 2015;25(5):514-27. doi: 10.1089/thy.2014.0257.
  34. Rai V, Maldonado AY, Burz DS, Reverdatto S, Schmidt AM, et al. Signal transduction in Receptor for Advanced Glycation End Products (RAGE): solution structure of C-terminal RAGE and its binding to mDia1. J Biol Chem. 2012;287(7):5133-44. doi: 10.1074/jbc.M111.277731.
  35. Xue J, Manigrasso M, Scalabrin M, Rai V, Reverdatto S, Burz DS, et al. Change in the Molecular Dimension of a RAGE-Ligand Complex Triggers RAGE Signaling. Structure. 2016;24(9):1509-22. doi: 10.1016/j.str.2016.06.021.
  36. Gaens KH, Niessen PM, Rensen SS, Buurman WA, Greve JW, Driessen A, et al. Endogenous formation of Nε-(carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis. J Hepatol. 2012;56(3):647-55. doi: 10.1016/j.jhep.2011.07.028.
  37. Gaens KH, Goossens GH, Niessen PM, van Greevenbroek MM, van der Kallen CJ, Niessen HW, et al. Nε-(carboxymethyl)lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance. Arterioscler Thromb Vasc Biol. 2014;34(6):1199-208. doi: 10.1161/ATVBAHA.113.302281.
  38. Gaens KH, Ferreira I, van de Waarenburg MP, van Greevenbroek MM, van der Kallen CJ, Dekker JM, et al. Protein-Bound Plasma Nε-(Carboxymethyl)lysine Is Inversely Associated With Central Obesity and Inflammation and Significantly Explain a Part of the Central Obesity-Related Increase in Inflammation: The Hoorn and CODAM Studies. Arterioscler Thromb Vasc Biol. 2015;35(12):2707-13. doi: 10.1161/ATVBAHA.115.306106.
  39. Steiner J, Schiltz K, Walter M, Wunderlich MT, Keilhoff G, Brisch R, et al. S100B serum levels are closely correlated with body mass index: an important caveat in neuropsychiatric research. Psychoneuroendocrinology. 2010;35(2):321-4. doi: 10.1016/j.psyneuen.2009.07.012.
  40. Arrigo T, Chirico V, Salpietro V, Munafò C, Ferraù V, Gitto E, et al. High-mobility group protein B1: a new biomarker of metabolic syndrome in obese children. Eur J Endocrinol. 2013;168(4):631-8. doi: 10.1530/EJE-13-0037.
  41. Gunasekaran MK, Viranaicken W, Girard AC, Festy F, Cesari M, Roche R, et al. Inflammation triggers high mobility group box 1 (HMGB1) secretion in adipose tissue, a potential link to obesity. Cytokine. 2013;64(1):103-11. doi: 10.1016/j.cyto.2013.07.017.
  42. Song F, Hurtado del Pozo C, Rosario R, Zou YS, Ananthakrishnan R, Xu X, et al. RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice. Diabetes. 2014;63(6):1948-65. doi: 10.2337/db13-1636.
  43. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes. 1974;23(2):105-11.
  44. Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ, et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol. 2004;24(7):1266-71.
  45. Inoue K, Kawahara K, Biswas KK, Ando K, Mitsudo K, Nobuyoshi M, et al. HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol. 2007;16(3):136-43.
  46. Hanssen NM, Wouters K, Huijberts MS, Gijbels MJ, Sluimer JC, Scheijen JL, et al. Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. Eur Heart J. 2014;35(17):1137-46. doi: 10.1093/eurheartj/eht402.
  47. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 1998;4(9):1025-31.
  48. Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC, et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes. 2008;57(9):2461-9. doi: 10.2337/db07-1808.
  49. Koulis C, Kanellakis P, Pickering RJ, Tsorotes D, Murphy AJ, Gray SP, et al. Role of bone-marrow- and non-bone-marrow-derived receptor for advanced glycation end-products (RAGE) in a mouse model of diabetes-associated atherosclerosis. Clin Sci (Lond). 2014;127(7):485-97. doi: 10.1042/CS20140045.
  50. Bu DX, Rai V, Shen X, Rosario R, Lu Y, D'Agati V, et al. Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice. Circ Res. 2010;106(6):1040-51. doi: 10.1161/CIRCRESAHA.109.201103.
  51. Zhai DX, Kong QF, Xu WS, Bai SS, Peng HS, Zhao K, et al. RAGE expression is up-regulated in human cerebral ischemia and pMCAO rats. Neurosci Lett. 2008;445(1):117-21. doi: 10.1016/j.neulet.2008.08.077.
  52. Hassid BG, Nair MN, Ducruet AF, Otten ML, Komotar RJ, Pinsky DJ, et al. Neuronal RAGE expression modulates severity of injury following transient focal cerebral ischemia. J Clin Neurosci. 2009;16(2):302-6. doi: 10.1016/j.jocn.2007.12.011.
  53. Kamide T, Kitao Y, Takeichi T, Okada A, Mohri H, Schmidt AM, et al. RAGE mediates vascular injury and inflammation after global cerebral ischemia. Neurochem Int. 2012;60(3):220-8. doi: 10.1016/j.neuint.2011.12.008.
  54. Li D, Lei C, Zhang S, Zhang S, Liu M, Wu B. Blockade of high mobility group box-1 signaling via the receptor for advanced glycation end-products ameliorates inflammatory damage after acute intracerebral hemorrhage. Neurosci Lett. 2015;609:109-19. doi: 10.1016/j.neulet.2015.10.035.
  55. Abel M, Ritthaler U, Zhang Y, Deng Y, Schmidt AM, Greten J, et al. Expression of receptors for advanced glycosylated end-products in renal disease. Nephrol Dial Transplant. 1995;10(9):1662-7.
  56. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol. 2000;11(9):1656-66.
  57. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest. 2001;108(2):261-8.
  58. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol. 2003;162(4):1123-37.
  59. Inagi R, Yamamoto Y, Nangaku M, Usuda N, Okamato H, Kurokawa K, et al. A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in RAGE/iNOS transgenic mice. Diabetes. 2006;55(2):356-66.
  60. Myint KM, Yamamoto Y, Doi T, Kato I, Harashima A, Yonekura H, et al. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes. 2006;55(9):2510-22.
  61. Flyvbjerg A, Denner L, Schrijvers BF, Tilton RG, Mogensen TH, Paludan SR, et al. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes. 2004;53(1):166-72.
  62. Jensen LJ, Denner L, Schrijvers BF, Tilton RG, Rasch R, Flyvbjerg A. Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice. J Endocrinol. 2006;188(3):493-501.
  63. Reiniger N, Lau K, McCalla D, Eby B, Cheng B, Lu Y, et al. Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes. 2010;59(8):2043-54. doi: 10.2337/db09-1766.
  64. Zheng S, Noonan WT, Metreveli NS, Coventry S, Kralik PM, Carlson EC, et al. Development of late-stage diabetic nephropathy in OVE26 diabetic mice. Diabetes. 2004;53(12):3248-57.
  65. Sun M, Yokoyama M, Ishiwata T, Asano G. Deposition of advanced glycation end products (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat. Int J Exp Pathol. 1998;79(4):207-22.
  66. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res. 2003;92(7):785-92.
  67. Nielsen JM, Kristiansen SB, Nørregaard R, Andersen CL, Denner L, Nielsen TT, et al. Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice. Eur J Heart Fail. 2009;11(7):638-47. doi: 10.1093/eurjhf/hfp070.
  68. Mohammadzadeh F, Desjardins JF, Tsoporis JN, Proteau G, Leong-Poi H, Parker TG. S100B: role in cardiac remodeling and function following myocardial infarction in diabetes. Life Sci. 2013;92(11):639-47. doi: 10.1016/j.lfs.2012.09.011.
  69. Kirsch S, Iroku-Malize T. Eye Conditions in Older Adults: Diabetic Retinopathy. FP Essent. 2016;445:29-37; quiz 38-9.
  70. Wang Y, Vom Hagen F, Pfister F, Bierhaus A, Feng Y, Gans R, et al. Receptor for advanced glycation end product expression in experimental diabetic retinopathy. Ann N Y Acad Sci. 2008;1126:42-5. doi: 10.1196/annals.1433.063.
  71. Barile GR, Pachydaki SI, Tari SR, Lee SE, Donmoyer CM, Ma W, et al. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 2005;46(8):2916-24.
  72. Mohammad G, Siddiquei MM, Othman A, Al-Shabrawey M, Abu El-Asrar AM. High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina. Exp Eye Res. 2013;107:101-9. doi: 10.1016/j.exer.2012.12.009.
  73. Abu El-Asrar AM, Mohammad G, Nawaz MI, Siddiquei MM. High-Mobility Group Box-1 Modulates the Expression of Inflammatory and Angiogenic Signaling Pathways in Diabetic Retina. Curr Eye Res. 2015;40(11):1141-52. doi: 10.3109/02713683.2014.982829.
  74. McVicar CM, Ward M, Colhoun LM, Guduric-Fuchs J, Bierhaus A, Fleming T, et al. Role of the receptor for advanced glycation endproducts (RAGE) in retinal vasodegenerative pathology during diabetes in mice. Diabetologia. 2015;58(5):1129-37. doi: 10.1007/s00125-015-3523-x.
  75. Goova MT, Li J, Kislinger T, Qu W, Lu Y, Bucciarelli LG, et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol. 2001;159(2):513-25.
  76. Juranek JK, Kothary P, Mehra A, Hays A, Brannagan TH, Schmidt AM. Increased expression of the receptor for advanced glycation end-products in human peripheral neuropathies. Brain Behav. 2013;3(6):701-709. doi: 10.1002/brb3.176.
  77. Malmstedt J, Karvestedt L, Swedenborg J, Brismar K. The receptor for advanced glycation end products and risk of peripheral arterial disease, amputation or death in type 2 diabetes: a population-based cohort study. Cardiovasc Diabetol. 2015;14:93. doi: 10.1186/s12933-015-0257-5.
  78. Lalla E, Lamster IB, Feit M, Huang L, Spessot A, Qu W, et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest. 2000;105(8):1117-24.
  79. Neves D. Advanced glycation end-products: a common pathway in diabetes and age-related erectile dysfunction. Free Radic Res. 2013;47 Suppl 1:49-69. doi: 10.3109/10715762.2013.821701.
  80. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008;22(10):3716-27. doi: 10.1096/fj.08-109033.
  81. Zhang L, Bukulin M, Kojro E, Roth A, Metz VV, Fahrenholz F, et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem. 2008;283(51):35507-16. doi: 10.1074/jbc.M806948200.
  82. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J. 2003;370(Pt 3):1097-109.
  83. Wang P, Huang R, Lu S, Xia W, Cai R, Sun H, et al. RAGE and AGEs in Mild Cognitive Impairment of Diabetic Patients: A Cross-Sectional Study. PLoS One. 2016;11(1). doi.org/10.1371/journal.pone.0145521.
  84. Heier M, Margeirsdottir HD, Gaarder M, Stensaeth KH, Brunborg C, Torjesen PA, et al. Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study. Cardiovasc Diabetol. 2015;14:126. doi: 10.1186/s12933-015-0292-2.
  85. Thomas MC, Woodward M, Neal B, Li Q, Pickering R, Marre M, et al. Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes. Diabetes Care. 2015 Oct;38(10):1891-7. doi: 10.2337/dc15-0925.
  86. Skrha J, Soupal J, Loni Ekali G, Prazny M, Kalousova M, Kvasnicka J, et al. Skin autofluorescence relates to soluble receptor for advanced glycation end-products and albuminuria in diabetes mellitus. J Diabetes Res. 2013;2013. doi: 10.1155/2013/650694.
  87. Koyama H, Tanaka S, Monden M, Shoji T, Morioka T, Fukumoto S, et al. Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: randomized controlled trial (PioRAGE). Atherosclerosis. 2014;234(2):329-334. doi.org/10.1016/j.atherosclerosis.2014.03.025.
  88. Brix JM, Hollerl F, Kopp HP, Schernthaner GH, Schernthaner G. The soluble form of the receptor of advanced glycation endproducts increases after bariatric surgery in morbid obesity. Int J Obes (Lond). 2012 Nov;36(11):1412-7. doi: 10.1038/ijo.2012.107.
  89. Tam HL, Shiu SW, Wong Y, Chow WS, Betteridge DJ, Tan KC. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis. 2010;209(1):173-7. doi: 10.1016/j.atherosclerosis.2009.08.031.
  90. Lanati N, Emanuele E, Brondino N, Geroldi D. Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation. Curr Vasc Pharmacol. 2010;8(1):86-92.
  91. Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, et al. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest. 2012;122(4):1377-92. doi: 10.1172/JCI58642.
  92. Manigrasso MB, Pan J, Rai V, Zhang J, Reverdatto S, Quadri N, et al. Small Molecule Inhibition of Ligand-Stimulated RAGE-DIAPH1 Signal Transduction. Sci Rep. 2016;6:22450. doi: 10.1038/srep22450.
  93. Ahmed N. Advanced glycation endproducts--role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005;67(1):3-21.
  94. Elosta A, Ghous T, Ahmed N. Natural products as anti-glycation agents: possible therapeutic potential for diabetic complications. Curr Diabetes Rev. 2012;8(2):92-108.
  95. Kabadi SV, Stoica BA, Zimmer DB, Afanador L, Duffy KB, Loane DJ, et al. S100B inhibition reduces behavioral and pathologic changes in experimental traumatic brain injury. J Cereb Blood Flow Metab. 2015;35(12):2010-20. doi: 10.1038/jcbfm.2015.165.
  96. Pruenster M, Vogl T, Roth J, Sperandio M. S100A8/A9: From basic science to clinical application. Pharmacol Ther. 2016 Nov;167:120-131. doi: 10.1016/j.pharmthera.2016.07.015.
  97. Matsuoka N, Itoh T, Watarai H, Sekine-Kondo E, Nagata N, Okamoto K, et al. High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice. J Clin Invest. 2010;120(3):735-43. doi: 10.1172/JCI41360.
  98. Chen Y, Yan SS, Colgan J, Zhang HP, Luban J, Schmidt AM, et al. Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol. 2004;173(2):1399-1405.
  99. Christaki E, Opal SM, Keith JC, Kessimian N, Palardy JE, Parejo NA, et al. A monoclonal antibody against RAGE alters gene expression and is protective in experimental models of sepsis and pneumococcal pneumonia. Shock. 2011;35(5):492-8. doi: 10.1097/SHK.0b013e31820b2e1c.
  100. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest. 2004;113(11):1641-1650.
  101. Lutterloh EC, Opal SM, Pittman DD, Keith JC, Tan XY, Clancy BM, et al. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care. 2007;11(6):R122.
  102. van Zoelen MA, Achouiti A, van der Poll T. RAGE during infectious diseases. Front Biosci (Schol Ed). 2011;3:1119-1132.
  103. Guo WA, Knight PR, Raghavendran K. The receptor for advanced glycation end products and acute lung injury/acute respiratory distress syndrome. Intensive Care Med. 2012;38(10):1588-1598.
  104. Sukkar MB, Ullah MA, Gan WJ, Wark PA, Chung KF, Hughes JM, et al. RAGE: a new frontier in chronic airways disease. Br J Pharmacol. 2012;167(6):1161-76. doi: 10.1111/j.1476-5381.2012.01984.x.
  105. Englert JM, Kliment CR, Ramsgaard L, Milutinovic PS, Crum L, Tobolewski JM, et al. Paradoxical function for the receptor for advanced glycation end products in mouse models of pulmonary fibrosis. Int J Clin Exp Pathol. 2011;4(3):241-254.

 Top ↑

Copyright: © 2017 Hurtado Del Pozo C, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.